成年人减肥药物的药物遗传学相互作用：系统评价和荟萃分析。
Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.
机构信息
Clinical Enteric Neuroscience Translational & Epidemiological Research (CENTER), Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
Library, Public Service Department, Mayo Clinic, Rochester, MN 55905, USA.
出版信息
Pharmacogenomics. 2023 Apr;24(5):283-295. doi: 10.2217/pgs-2022-0192. Epub 2023 Mar 31.
To analyze roles of single nucleotide variants (SNVs) on weight loss with US FDA-approved medications. We searched the literature up until November 2022. Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines were followed. 14 studies were included in qualitative analysis and seven in meta-analysis. SNVs in , , , , , , and were evaluated relative to weight loss with glucagon-like peptide-1 agonists (13 studies) or naltrexone-bupropion (one study). gene (rs1049353), gene (rs6923761, rs10305420), gene (rs7903146) were associated with weight loss in at least one study involving glucagon-like peptide-1 agonist(s). The meta-analysis did not identify any consistent effect of SNVs. Pharmacogenetic interactions for exenatide, liraglutide, naltrexone-bupropion and weight loss were identified, but the directionality was inconsistent.
分析美国食品和药物管理局批准的药物治疗体重减轻的单核苷酸变异（SNV）的作用。我们检索了截至 2022 年 11 月的文献。遵循系统评价和荟萃分析的首选报告项目指南。14 项研究进行了定性分析，7 项进行了荟萃分析。评估了与胰高血糖素样肽-1 激动剂（13 项研究）或纳曲酮-安非他酮（一项研究）相关的 、 、 、 、 、 基因（rs1049353）、 基因（rs6923761、rs10305420）、 基因（rs7903146）中的 SNV 与体重减轻的关系。至少有一项涉及胰高血糖素样肽-1 激动剂的研究表明， 基因（rs1049353）、 基因（rs6923761、rs10305420）和 基因（rs7903146）中的 SNV 与体重减轻有关。荟萃分析没有发现 SNV 的任何一致影响。确定了 exenatide、liraglutide、naltrexone-bupropion 和体重减轻的药物遗传学相互作用，但方向性不一致。
Zotero 插件